Effectiveness and Safety of Yiqitongluo Granule for Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

2197 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-29

Study Completion Date

2017-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the prospective study is to evaluate the effectiveness and safety of Yiqitongluo granule in the treatment of stroke with qi-deficiency and blood-stasis in more than sixy hospitals all over China.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome

NCT04408261

Stroke, Ischemic Coronary Artery Disease Angina Pectoris, Stable +1 more

UNKNOWN PHASE2

Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke

NCT01762163

Ischemic Stroke

COMPLETED PHASE4

Yiqi Huoxue Demolition and Recipes on Recovery Stage of Cerebral Infarction

NCT02846207

Cerebral Infarction

UNKNOWN NA

Clinical Evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy

NCT03354026

Intracerebral Hemorrhage, Hypertensive Traditional Chinese Medicine

UNKNOWN PHASE4

A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.

NCT02526225

Ischemic Stroke

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Yiqitongluo group

Yiqitongluo granule 12g each time, 3 times a daily for 4 weeks.

Group Type EXPERIMENTAL

Yiqitongluo granule

Intervention Type DRUG

administered after dissolved

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Yiqitongluo granule

administered after dissolved

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* mild and moderate ischemic stroke patient with 4-25 NIHSS score
* stable patients within 1 week to 3 months
* sign informed consent before study

Exclusion Criteria

* CT shows cerebral hemorrhage disease: such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, and subarachnoid hemorrhage
* severe disturbance of consciousness
* dysphagia
* TIA
* hemorrhagic diathesis
* patient with malignant tumor whose expected lifetime is less than 3 months
* allergic constitution
* gestation period, lactation period, woman with the possibility or plan of pregnancy
* those who participated in other clinical trials within 3 months or taking part in other clinical trials

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No